Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Enzo Biochem, Inc. ENZ NYSE

NYSE • Healthcare • Medical - Diagnostics & Research • US • USD

SharesGrow Score
37/100
0/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Enzo Biochem, Inc. (ENZ) — Analyst outlook / Analyst consensus target is. Based on 2 analyst ratings, the consensus is bullish — 1 Buy, 1 Hold.

ENZ Analyst Ratings

Buy
2
Ratings
1 Buy
1 Hold
Based on 2 analysts giving stock ratings to Enzo Biochem, Inc. in the past 3 months
Rating breakdown
Buy
1 50%
Hold
1 50%
50%
Buy
1 analysts
50%
Hold
1 analysts
0%
Sell
0 analysts

People Also View

SHC
SHC
Sotera Health Company
$15.93
+1.46%
 OLK
OLK
Olink Holding AB (publ)
$26.08
+0.31%
 CSTL
CSTL
Castle Biosciences, Inc.
$24.37
+3.57%
 GTH
GTH
Genetron Holdings Limited
$4.03
+0.12%
 FONR
FONR
FONAR Corporation
$18.76
+0.27%
 STIM
STIM
Neuronetics, Inc.
$1.43
+2.88%
 BDSX
BDSX
Biodesix, Inc.
$12.14
-9.13%
 SERA
SERA
Sera Prognostics, Inc.
$2.14
+0.47%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message